ClinicalTrials.gg
CompletedNCT00770653Updated Oct 6, 2010Results posted

Efficacy of Pioglitazone/Metformin Combination Therapy in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia.

A Phase 3 interventional study of Pioglitazone and Metformin and Glimepiride and Metformin in Diabetes Mellitus and Dyslipidemias, sponsored by Takeda. Completed at 64 sites in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2010-10-06.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's title name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
305
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 — 7 open to participants now, 8 under way, 1 of them phase 3. Pioglitazone · Diabetes Mellitus, Type 2.

Enrollment
31st of 122
305 · median 103
Started
2007
with 11 others
Phase 3
31 of 122
1 open now
Registered
50th of 122
by date
Lead sponsor
27 of 122
Takeda

Among the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, this one is the 31st largest by enrollment, is one of 12 that started in 2007, is one of 31 in phase 3, and was the 50th registered.

Diabetes Mellitus, Type 2

10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About pioglitazone

Pioglitazone: first FDA approval 1999 (ACTOS), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to compare pioglitazone and metformin combination therapy, twice daily (BID), to glimepiride and metformin combination therapy for treating diabetic subjects with dyslipidemia.

Read the detailed description

Insulin resistance is a major endocrinopathy preceding the development of hyperglycemia, diabetic dyslipidemia and cardiovascular disease in type 2 diabetes. The most common pattern of dyslipidemia in patients with type 2 diabetes are elevated triglyceride levels, decreased hih-density lipoprotein cholesterol and a predominance of small dense low-density lipoprotein particles. Each of these dyslipidemia features is associated with an increased risk of cardiovascular events.

Pioglitazone and Metformin are established drugs which can be used for the treatment of type 2 diabetes. This study will investigate the effects of treatment with fixed Pioglitazone/Metformin combination therapy of Metformin and Glimepiride in Metformin-pretreated type 2 diabetic patients with dyslipidemia.

Total participation time in this study is anticipated to be approximately 24 weeks.

03

Conditions studied

  • Diabetes Mellitus
  • Dyslipidemias

Keywords

  • Glucose Metabolism Disorder
  • Dysmetabolic Syndrome
  • Type II Diabetes
  • Diabetes Mellitus, Lipoatrophic
  • Dyslipidemia
  • Hyperlipidemias
  • Drug Therapy
04

In context

Diabetes Mellitus, Type 2 Reclassified

10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 305 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes according to the American Diabetes Association Criteria.
  • Treatment with individual maximal tolerated dose of metformin (850 - 2000 mg) as monotherapy within the last 12 weeks.
  • Glycosylated greater than or equal to 6.5% and less than or equal to 9%.
  • Dyslipidemia defined as high-density lipoprotein cholesterol less than or equal to 1.03 mmol/l (40 mg/dL) and/or triglycerides greater than or equal to 1.7 mmol/l (150 mg/dL).
  • Females of who are sexually active must agree to use adequate , and can neither be pregnant nor lactating from Screening throughout the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes mellitus.
  • Insulin-dependent type 2 diabetes mellitus.
  • Treatment or history of treatment with any insulin formulation other than emergency for more than 2 weeks.
  • Treatment with other oral antidiabetic drugs in addition to metformin within the last 12 weeks.
  • Anamnestic history of to the study drugs or to drugs with similar chemical structures.
  • Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:

    • Heparin (and heparin-like drugs)
    • coumarin
    • phenprocoumon
    • hirudin
    • Protein C
    • Fondaparinux
    • antithrombin III
    • Peroxisome Proliferation Activating Receptor (gamma) agonists
    • Treatment within the last 12 weeks with:

      • fibrates
      • gemfibrozil
      • niacin
      • months
      • Rifampicin
    • Changes in dosage of any statin treatment to lower low-density lipoprotein within 2 weeks before study entry and during study participation interval.
    • Changes in dosage of any anticoagulant treatment with acetyl salicylic acid and/or clopidogrel within 2 weeks before study entry and during study participation interval.
    • Start of statin and/or anticoagulant treatment during study participation interval.
  • History of severe or multiple allergies and/ or acute severe infections.
  • Have had more than one unexplained episode of severe hypoglycemia (defined as requiring assistance of another person due to disabling hypoglycemia) within 6 months prior to screening visit.
  • Progressive fatal disease.
  • Any elective surgery during study participation.
  • History of drug or alcohol abuse within the last 5 years.
  • A history of significant cardiovascular ( stage I - IV), respiratory, gastrointestinal, hepatic ( and/or aspartate aminotransferase greater than 2.5 times the reference range), renal (serum creatinine greater than 1.2 mg/dL in women and greater than 1.5 mg/dL in men, less than 60 ml/min as estimated by the Cockroft-Gault formula), neurological, psychiatric and/or hematological disease as judged by the investigator, history of macular edema.
  • Blood donation within the last 30 days.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
305 participants (actual)

Study arms

  • Experimental
    Pioglitazone 15 mg and Metformin 850 mg BID

    Drug: Pioglitazone and Metformin

  • Active comparator
    Glimepiride 2 mg and Metformin 850 mg BID

    Drug: Glimepiride and Metformin

Interventions

  • DrugPioglitazone and Metformin

    Drug pages: Pioglitazone · Metformin

    Pioglitazone 15 mg/metformin 850 mg combination tablets, orally, twice daily and glimepiride placebo-matching tablets, orally, once daily and metformin placebo-matching tablets, orally, twice daily for up to 24 weeks.

    Also known as: ACTOS®, AD-4833, OPIMET

  • DrugGlimepiride and Metformin

    Drug pages: Glimepiride · Metformin

    Pioglitazone/metformin placebo-matching combination tablets, orally, twice daily and glimepiride 2 mg, tablets, orally, once daily and metformin 850 mg, tablets, orally, twice daily for up to 24 weeks.

    Also known as: Amaryl, Glista

07

What researchers measure

Primary outcomes

  1. The Mean Increase From Baseline in High-Density Lipoprotein Cholesterol.

    The increase in High-Density Lipoprotein (HDL) Cholesterol collected at week 24 or final visit and HDL-Cholesterol collected at baseline.

    Time frame: Baseline and Week 24.

Secondary outcomes

  1. Change From Baseline in High-Density Lipoprotein Cholesterol.

    The change between HDL-Cholesterol collected at week 24 or final visit and HDL-Cholesterol collected at baseline.

    Time frame: Baseline and Week 24.

  2. Change From Baseline in High-Density Lipoprotein/Low-Density Lipoprotein Ratio.

    The change between High-Density Lipoprotein/Low-Density Lipoprotein Ratio collected at week 24 or final visit and High-Density Lipoprotein/Low-Density Lipoprotein Ratio collected at baseline.

    Time frame: Baseline and Week 24.

  3. Change From Baseline in Triglycerides.

    The change between the value of Triglycerides collected at week 24 or final visit and Triglycerides collected at baseline.

    Time frame: Baseline and Week 24.

  4. Change From Baseline in Low-Density Lipoprotein Subfractions.

    The change between the value of Low-Density Lipoprotein Subfractions collected at week 24 or final visit and Low-Density Lipoprotein Subfractions collected at baseline.

    Time frame: Baseline and Week 24.

  5. Change From Baseline in Low-Density Lipoprotein Cholesterol.

    The change between Low-Density Lipoprotein Cholesterol collected at week 24 or final visit and Low-Density Lipoprotein Cholesterol collected at baseline.

    Time frame: Baseline and Week 24.

  6. Change From Baseline in Glycosylated Hemoglobin.

    The change between the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 24 or final visit and Glycosylated Hemoglobin collected at baseline.

    Time frame: Baseline and Week 24.

  7. Change From Baseline in Fasting Intact Proinsulin.

    The change between Fasting Intact Proinsulin collected at week 24 or final visit and Fasting Intact Proinsulin collected at baseline.

    Time frame: Baseline and Week 24.

  8. Change From Baseline in Fasting Glucose.

    The change between Fasting Glucose collected at week 24 or final visit and Fasting Glucose collected at baseline.

    Time frame: Baseline and Week 24.

  9. Change From Baseline in Adiponectin.

    The change between Adiponectin collected at week 24 or final visit and Adiponectin collected at baseline.

    Time frame: Baseline and Week 24.

  10. Change From Baseline in High Sensitivity C-reactive Protein (Original).

    The change between the value of High Sensitivity C-reactive Protein collected at week 24 or final visit and High Sensitivity C-reactive Protein collected at baseline.

    Time frame: Baseline and Week 24.

  11. Change From Baseline in High Sensitivity C-reactive Protein (≤ 10 mg/L).

    The change between the value of High Sensitivity C-reactive Protein less than or equal to 10 mg/L collected at week 24 or final visit and High Sensitivity C-reactive Protein less than or equal to 10 mg/L collected at baseline.

    Time frame: Baseline and Week 24.

  12. Change From Baseline in Systolic Blood Pressure.

    The change between Systolic Blood Pressure measured at week 24 or final visit and Systolic Blood Pressure measured at baseline.

    Time frame: Baseline and Week 24.

  13. Change From Baseline in Diastolic Blood Pressure.

    The change between Diastolic Blood Pressure measured at week 24 or final visit and Diastolic Blood Pressure measured at baseline.

    Time frame: Baseline and Week 24.

  14. Intake of Study Medication Greater Than 80% and Less Than 120%.

    The change between the Intake of study medication greater than 80% at week 24 or final visit and Baseline and the Intake of study medication greater than 80% at baseline.

    Time frame: Baseline and Week 24.

  15. Change From Baseline in Nitrotyrosine.

    The change between the value of Nitrotyrosine collected at week 24 or final visit and Nitrotyrosine collected at baseline.

    Time frame: Baseline and Week 24.

  16. Change From Baseline in Soluble CD40 Ligand.

    The change between the value of Soluble CD40 Ligand collected at week 24 or final visit and Soluble CD40 Ligand collected at baseline.

    Time frame: Baseline and Week 24.

  17. Change From Baseline in Matrix Metallo Proteinase-9.

    The change between the value of Baseline in Matrix Metallo Proteinase-9 collected at week 24 or final visit and Baseline in Matrix Metallo Proteinase-9 collected at baseline.

    Time frame: Baseline and Week 24.

  18. Change From Baseline in Soluble Intracellular Adhesion Molecule.

    The change between the value of Baseline in Soluble Intracellular Adhesion molecule at week 24 or final visit and Baseline in Soluble Intracellular Adhesion molecule collected at baseline.

    Time frame: Baseline and Week 24.

  19. Change From Baseline in Soluble Vascular Cell Adhesion Molecule.

    The change between the value of Soluble Vascular Cell Adhesion Molecule collected at week 24 or final visit and Soluble Vascular Cell Adhesion Molecule collected at baseline.

    Time frame: Baseline and Week 24.

  20. Change From Baseline in Thromboxane B2.

    The change between the value of Thromboxane B2 collected at week 24 or final visit and Thromboxane B2 collected at baseline.

    Time frame: Baseline and Week 24.

  21. Change From Baseline in Platelet Function.

    The change between the value of Platelet Function by PFA 100 collected at week 24 or final visit and Platelet Function by PFA 100 collected at baseline.

    Time frame: Baseline and Week 24.

  22. Change From Baseline in E-Selectin.

    The change between the value of E-Selectin collected at week 24 or final visit and E-Selectin collected at baseline.

    Time frame: Baseline and Week 24.

  23. Change From Baseline in Von-Willebrand Factor.

    The change between the value of Von-Willebrand Factor collected at week 24 or final visit and Von-Willebrand Factor collected at baseline.

    Time frame: Baseline and Week 24.

  24. Change From Baseline in Erythrocyte Deformability (0.30%).

    The change between the 0.30 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.

    Time frame: Baseline and Week 24.

  25. Change From Baseline in Erythrocyte Deformability (0.60%)

    The change between the 0.60 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.

    Time frame: Baseline and Week 24.

  26. Change From Baseline in Erythrocyte Deformability (1.20).

    The change between the 1.20 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.

    Time frame: Baseline and Week 24.

  27. Change From Baseline in Erythrocyte Deformability (3.00).

    The change between the 3.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.

    Time frame: Baseline and Week 24.

  28. Change From Baseline in Erythrocyte Deformability (6.00).

    The change between the 6.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.

    Time frame: Baseline and Week 24.

  29. Change From Baseline in Erythrocyte Deformability (12.00).

    The change between the 12.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.

    Time frame: Baseline and Week 24.

  30. Change From Baseline in Erythrocyte Deformability (30.00).

    The change between the 30.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.

    Time frame: Baseline and Week 24.

  31. Change From Baseline in Erythrocyte Deformability (60.00).

    The change between the 60.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.

    Time frame: Baseline and Week 24.

08

Results

Posted Oct 6, 2010

Participant flow

Subjects were enrolled at 61 investigative sites in Germany from 03 April 2007 to 13 May 2009.

Participant flow — Overall Study
MilestonePioglitazone 15 mg and Metformin 850 mg BIDGlimepiride 2 mg and Metformin 850 mg BID
Started155150
Completed123121
Not completed3229
Withdrew: Adverse event135
Withdrew: Protocol violation86
Withdrew: Withdrawal by subject47
Withdrew: Lack of compliance14
Withdrew: Worsening of glycosolated hemoglobin22
Withdrew: Fasting glucose > 240 mg/dl21
Withdrew: > three moderate hypoglycemic episodes02
Withdrew: Lost to follow-up12
Withdrew: Physician decision10

Outcome measures

PrimaryThe Mean Increase From Baseline in High-Density Lipoprotein Cholesterol.

The increase in High-Density Lipoprotein (HDL) Cholesterol collected at week 24 or final visit and HDL-Cholesterol collected at baseline.

Time frame:
Baseline and Week 24.
Reported as:
Least squares mean · mg/dL
The Mean Increase From Baseline in High-Density Lipoprotein Cholesterol.
mg/dLPioglitazone 15 mg and Metformin 850 mg BIDGlimepiride 2 mg and Metformin 850 mg BID
The Mean Increase From Baseline in High-Density Lipoprotein Cholesterol.3.2 ± 9.7-0.3 ± 11.0
Statistical analysis
  • Pioglitazone 15 mg and Metformin 850 mg BID vs Glimepiride 2 mg and Metformin 850 mg BID · ANCOVA · p = 0.0018 · Mean difference (final values): 3.2670 · 95% CI 1.2264 to 5.3076
SecondaryChange From Baseline in High-Density Lipoprotein Cholesterol.

The change between HDL-Cholesterol collected at week 24 or final visit and HDL-Cholesterol collected at baseline.

Time frame:
Baseline and Week 24.
Reported as:
Least squares mean · mg/dL
Change From Baseline in High-Density Lipoprotein Cholesterol.
mg/dLPioglitazone 15 mg and Metformin 850 mg BIDGlimepiride 2 mg and Metformin 850 mg BID
Change From Baseline in High-Density Lipoprotein Cholesterol.3.3 ± 9.6-0.4 ± 11.1
Statistical analysis
  • Pioglitazone 15 mg and Metformin 850 mg BID vs Glimepiride 2 mg and Metformin 850 mg BID · ANCOVA · p = 0.0018 · Mean difference (final values): 3.2670 · 95% CI 1.2264 to 5.3076Deviation from the normal distribution assumption was detected for original and rank-transformed data for all time-points due to p-value of Shapiro-Wilk test, indicating the normal distribution assumption might be distrusted for HDL-cholesterol data.
SecondaryChange From Baseline in High-Density Lipoprotein/Low-Density Lipoprotein Ratio.

The change between High-Density Lipoprotein/Low-Density Lipoprotein Ratio collected at week 24 or final visit and High-Density Lipoprotein/Low-Density Lipoprotein Ratio collected at baseline.

Time frame:
Baseline and Week 24.
Reported as:
Least squares mean · mg/dL
Change From Baseline in High-Density Lipoprotein/Low-Density Lipoprotein Ratio.
mg/dLPioglitazone 15 mg and Metformin 850 mg BIDGlimepiride 2 mg and Metformin 850 mg BID
Change From Baseline in High-Density Lipoprotein/Low-Density Lipoprotein Ratio.0.1 ± 0.80.3 ± 0.7
Statistical analysis
  • Pioglitazone 15 mg and Metformin 850 mg BID vs Glimepiride 2 mg and Metformin 850 mg BID · ANCOVA · p = 0.1167 · Mean difference (final values): -0.1311 · 95% CI -0.2951 to 0.0329
SecondaryChange From Baseline in Triglycerides.

The change between the value of Triglycerides collected at week 24 or final visit and Triglycerides collected at baseline.

Time frame:
Baseline and Week 24.
Reported as:
Least squares mean · mg/dL
Change From Baseline in Triglycerides.
mg/dLPioglitazone 15 mg and Metformin 850 mg BIDGlimepiride 2 mg and Metformin 850 mg BID
Change From Baseline in Triglycerides.-40.9 ± 113.8-16.7 ± 121.6
Statistical analysis
  • Pioglitazone 15 mg and Metformin 850 mg BID vs Glimepiride 2 mg and Metformin 850 mg BID · ANCOVA · p = 0.1012 · Mean difference (final values): -17.9479 · 95% CI -39.4331 to 3.5373
SecondaryChange From Baseline in Low-Density Lipoprotein Subfractions.

The change between the value of Low-Density Lipoprotein Subfractions collected at week 24 or final visit and Low-Density Lipoprotein Subfractions collected at baseline.

Time frame:
Baseline and Week 24.
Reported as:
Least squares mean · mg/dL
Change From Baseline in Low-Density Lipoprotein Subfractions.
mg/dLPioglitazone 15 mg and Metformin 850 mg BIDGlimepiride 2 mg and Metformin 850 mg BID
Change From Baseline in Low-Density Lipoprotein Subfractions.6.2 ± 17.56.1 ± 26.4
Statistical analysis
  • Pioglitazone 15 mg and Metformin 850 mg BID vs Glimepiride 2 mg and Metformin 850 mg BID · ANCOVA · p = 0.7486 · Mean difference (final values): 3.1292 · 95% CI -17.0109 to 23.2693
SecondaryChange From Baseline in Low-Density Lipoprotein Cholesterol.

The change between Low-Density Lipoprotein Cholesterol collected at week 24 or final visit and Low-Density Lipoprotein Cholesterol collected at baseline.

Time frame:
Baseline and Week 24.
Reported as:
Least squares mean · mg/dL
Change From Baseline in Low-Density Lipoprotein Cholesterol.
mg/dLPioglitazone 15 mg and Metformin 850 mg BIDGlimepiride 2 mg and Metformin 850 mg BID
Change From Baseline in Low-Density Lipoprotein Cholesterol.9.7 ± 34.711.2 ± 25.3
Statistical analysis
  • Pioglitazone 15 mg and Metformin 850 mg BID vs Glimepiride 2 mg and Metformin 850 mg BID · ANCOVA · p = 0.9464 · Mean difference (final values): -0.2355 · 95% CI -7.1253 to 6.6543
SecondaryChange From Baseline in Glycosylated Hemoglobin.

The change between the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 24 or final visit and Glycosylated Hemoglobin collected at baseline.

Time frame:
Baseline and Week 24.
Reported as:
Least squares mean · mg/dL
Change From Baseline in Glycosylated Hemoglobin.
mg/dLPioglitazone 15 mg and Metformin 850 mg BIDGlimepiride 2 mg and Metformin 850 mg BID
Change From Baseline in Glycosylated Hemoglobin.-0.83 ± 0.87-0.95 ± 0.85
Statistical analysis
  • Pioglitazone 15 mg and Metformin 850 mg BID vs Glimepiride 2 mg and Metformin 850 mg BID · ANCOVA · p = 0.0807 · Mean difference (final values): 0.1574 · 95% CI -0.0193 to 0.3341
SecondaryChange From Baseline in Fasting Intact Proinsulin.

The change between Fasting Intact Proinsulin collected at week 24 or final visit and Fasting Intact Proinsulin collected at baseline.

Time frame:
Baseline and Week 24.
Reported as:
Least squares mean · pmol/L
Change From Baseline in Fasting Intact Proinsulin.
pmol/LPioglitazone 15 mg and Metformin 850 mg BIDGlimepiride 2 mg and Metformin 850 mg BID
Change From Baseline in Fasting Intact Proinsulin.-5.18 ± 11.89-0.11 ± 9.84
Statistical analysis
  • Pioglitazone 15 mg and Metformin 850 mg BID vs Glimepiride 2 mg and Metformin 850 mg BID · ANCOVA · p = <.0001 · Mean difference (final values): -4.5039 · 95% CI -6.4222 to -2.5855
SecondaryChange From Baseline in Fasting Glucose.

The change between Fasting Glucose collected at week 24 or final visit and Fasting Glucose collected at baseline.

Time frame:
Baseline and Week 24.
Reported as:
Least squares mean · mg/dL
Change From Baseline in Fasting Glucose.
mg/dLPioglitazone 15 mg and Metformin 850 mg BIDGlimepiride 2 mg and Metformin 850 mg BID
Change From Baseline in Fasting Glucose.-21.6 ± 38.6-21.1 ± 40.4
Statistical analysis
  • Pioglitazone 15 mg and Metformin 850 mg BID vs Glimepiride 2 mg and Metformin 850 mg BID · ANCOVA · p = 0.7799 · Mean difference (final values): 1.0707 · 95% CI -6.4665 to 8.6079
SecondaryChange From Baseline in Adiponectin.

The change between Adiponectin collected at week 24 or final visit and Adiponectin collected at baseline.

Time frame:
Baseline and Week 24.
Reported as:
Least squares mean · μg/mL
Change From Baseline in Adiponectin.
μg/mLPioglitazone 15 mg and Metformin 850 mg BIDGlimepiride 2 mg and Metformin 850 mg BID
Change From Baseline in Adiponectin.6.79 ± 6.380.72 ± 2.73
Statistical analysis
  • Pioglitazone 15 mg and Metformin 850 mg BID vs Glimepiride 2 mg and Metformin 850 mg BID · ANCOVA · p = <.0001 · Mean difference (final values): 6.3161 · 95% CI 5.0994 to 7.5329
SecondaryChange From Baseline in High Sensitivity C-reactive Protein (Original).

The change between the value of High Sensitivity C-reactive Protein collected at week 24 or final visit and High Sensitivity C-reactive Protein collected at baseline.

Time frame:
Baseline and Week 24.
Reported as:
Least squares mean · mg/L
Change From Baseline in High Sensitivity C-reactive Protein (Original).
mg/LPioglitazone 15 mg and Metformin 850 mg BIDGlimepiride 2 mg and Metformin 850 mg BID
Change From Baseline in High Sensitivity C-reactive Protein (Original).-0.21 ± 8.98-0.04 ± 9.53
Statistical analysis
  • Pioglitazone 15 mg and Metformin 850 mg BID vs Glimepiride 2 mg and Metformin 850 mg BID · ANCOVA · p = 0.4131 · Mean difference (final values): -0.8323 · 95% CI -2.8312 to 1.1665
SecondaryChange From Baseline in High Sensitivity C-reactive Protein (≤ 10 mg/L).

The change between the value of High Sensitivity C-reactive Protein less than or equal to 10 mg/L collected at week 24 or final visit and High Sensitivity C-reactive Protein less than or equal to 10 mg/L collected at baseline.

Time frame:
Baseline and Week 24.
Reported as:
Mean · mg/L
Change From Baseline in High Sensitivity C-reactive Protein (≤ 10 mg/L).
mg/LPioglitazone 15 mg and Metformin 850 mg BIDGlimepiride 2 mg and Metformin 850 mg BID
Change From Baseline in High Sensitivity C-reactive Protein (≤ 10 mg/L).-0.87 ± 1.880.00 ± 1.83
Statistical analysis
  • Pioglitazone 15 mg and Metformin 850 mg BID vs Glimepiride 2 mg and Metformin 850 mg BID · ANCOVA · p = <.0001 · Mean difference (final values): -0.8847 · 95% CI -1.3067 to -0.4627
SecondaryChange From Baseline in Systolic Blood Pressure.

The change between Systolic Blood Pressure measured at week 24 or final visit and Systolic Blood Pressure measured at baseline.

Time frame:
Baseline and Week 24.
Reported as:
Least squares mean · mmHg
Change From Baseline in Systolic Blood Pressure.
mmHgPioglitazone 15 mg and Metformin 850 mg BIDGlimepiride 2 mg and Metformin 850 mg BID
Change From Baseline in Systolic Blood Pressure.-2.5 ± 14.80.5 ± 13.8
Statistical analysis
  • Pioglitazone 15 mg and Metformin 850 mg BID vs Glimepiride 2 mg and Metformin 850 mg BID · ANCOVA · p = 0.0929 · Mean difference (final values): -2.4903 · 95% CI -5.3979 to 0.4172
SecondaryChange From Baseline in Diastolic Blood Pressure.

The change between Diastolic Blood Pressure measured at week 24 or final visit and Diastolic Blood Pressure measured at baseline.

Time frame:
Baseline and Week 24.
Reported as:
Least squares mean · mmHg
Change From Baseline in Diastolic Blood Pressure.
mmHgPioglitazone 15 mg and Metformin 850 mg BIDGlimepiride 2 mg and Metformin 850 mg BID
Change From Baseline in Diastolic Blood Pressure.-1.3 ± 8.7-0.1 ± 8.8
Statistical analysis
  • Pioglitazone 15 mg and Metformin 850 mg BID vs Glimepiride 2 mg and Metformin 850 mg BID · ANCOVA · p = 0.3279 · Mean difference (final values): -0.8832 · 95% CI -2.6571 to 0.8906
SecondaryIntake of Study Medication Greater Than 80% and Less Than 120%.

The change between the Intake of study medication greater than 80% at week 24 or final visit and Baseline and the Intake of study medication greater than 80% at baseline.

Time frame:
Baseline and Week 24.
Reported as:
Number · participants
Intake of Study Medication Greater Than 80% and Less Than 120%.
participantsPioglitazone 15 mg and Metformin 850 mg BIDGlimepiride 2 mg and Metformin 850 mg BID
Intake of Study Medication Greater Than 80% and Less Than 120%.136137
Statistical analysis
  • Pioglitazone 15 mg and Metformin 850 mg BID vs Glimepiride 2 mg and Metformin 850 mg BID · Fisher Exact · p = 0.2895 · Fisher exact: -3.33 · 95% CI -14.83 to 8.39
SecondaryChange From Baseline in Nitrotyrosine.

The change between the value of Nitrotyrosine collected at week 24 or final visit and Nitrotyrosine collected at baseline.

Time frame:
Baseline and Week 24.
Reported as:
Least squares mean · nmol/L
Change From Baseline in Nitrotyrosine.
nmol/LPioglitazone 15 mg and Metformin 850 mg BIDGlimepiride 2 mg and Metformin 850 mg BID
Change From Baseline in Nitrotyrosine.-2.7 ± 93.232.5 ± 147.2
Statistical analysis
  • Pioglitazone 15 mg and Metformin 850 mg BID vs Glimepiride 2 mg and Metformin 850 mg BID · ANCOVA · p = 0.3517 · Mean difference (final values): -29.9516 · 95% CI -94.1999 to 34.2967
SecondaryChange From Baseline in Soluble CD40 Ligand.

The change between the value of Soluble CD40 Ligand collected at week 24 or final visit and Soluble CD40 Ligand collected at baseline.

Time frame:
Baseline and Week 24.
Reported as:
Least squares mean · pg/mL
Change From Baseline in Soluble CD40 Ligand.
pg/mLPioglitazone 15 mg and Metformin 850 mg BIDGlimepiride 2 mg and Metformin 850 mg BID
Change From Baseline in Soluble CD40 Ligand.-40.7 ± 248.6102.4 ± 379.8
Statistical analysis
  • Pioglitazone 15 mg and Metformin 850 mg BID vs Glimepiride 2 mg and Metformin 850 mg BID · ANCOVA · p = 0.1979 · Mean difference (final values): -151.4477 · 95% CI -386.2256 to 83.3302
SecondaryChange From Baseline in Matrix Metallo Proteinase-9.

The change between the value of Baseline in Matrix Metallo Proteinase-9 collected at week 24 or final visit and Baseline in Matrix Metallo Proteinase-9 collected at baseline.

Time frame:
Baseline and Week 24.
Reported as:
Least squares mean · ng/mL
Change From Baseline in Matrix Metallo Proteinase-9.
ng/mLPioglitazone 15 mg and Metformin 850 mg BIDGlimepiride 2 mg and Metformin 850 mg BID
Change From Baseline in Matrix Metallo Proteinase-9.31.4 ± 228.351.6 ± 216.4
Statistical analysis
  • Pioglitazone 15 mg and Metformin 850 mg BID vs Glimepiride 2 mg and Metformin 850 mg BID · ANCOVA · p = 0.7186 · Mean difference (final values): -24.8589 · 95% CI -163.3229 to 113.6052
SecondaryChange From Baseline in Soluble Intracellular Adhesion Molecule.

The change between the value of Baseline in Soluble Intracellular Adhesion molecule at week 24 or final visit and Baseline in Soluble Intracellular Adhesion molecule collected at baseline.

Time frame:
Baseline and Week 24.
Reported as:
Least squares mean · ng/mL
Change From Baseline in Soluble Intracellular Adhesion Molecule.
ng/mLPioglitazone 15 mg and Metformin 850 mg BIDGlimepiride 2 mg and Metformin 850 mg BID
Change From Baseline in Soluble Intracellular Adhesion Molecule.-13.0 ± 46.9-3.2 ± 50.0
Statistical analysis
  • Pioglitazone 15 mg and Metformin 850 mg BID vs Glimepiride 2 mg and Metformin 850 mg BID · ANCOVA · p = 0.5058 · Mean difference (final values): -9.9728 · 95% CI -39.9915 to 20.0459
SecondaryChange From Baseline in Soluble Vascular Cell Adhesion Molecule.

The change between the value of Soluble Vascular Cell Adhesion Molecule collected at week 24 or final visit and Soluble Vascular Cell Adhesion Molecule collected at baseline.

Time frame:
Baseline and Week 24.
Reported as:
Least squares mean · ng/mL
Change From Baseline in Soluble Vascular Cell Adhesion Molecule.
ng/mLPioglitazone 15 mg and Metformin 850 mg BIDGlimepiride 2 mg and Metformin 850 mg BID
Change From Baseline in Soluble Vascular Cell Adhesion Molecule.11.6 ± 160.63.3 ± 115.4
Statistical analysis
  • Pioglitazone 15 mg and Metformin 850 mg BID vs Glimepiride 2 mg and Metformin 850 mg BID · ANCOVA · p = 0.5230 · Mean difference (final values): 28.3988 · 95% CI -60.7193 to 117.5169
SecondaryChange From Baseline in Thromboxane B2.

The change between the value of Thromboxane B2 collected at week 24 or final visit and Thromboxane B2 collected at baseline.

Time frame:
Baseline and Week 24.
Reported as:
Least squares mean · pg/mL
Change From Baseline in Thromboxane B2.
pg/mLPioglitazone 15 mg and Metformin 850 mg BIDGlimepiride 2 mg and Metformin 850 mg BID
Change From Baseline in Thromboxane B2.-216.4 ± 842.9527.8 ± 1190.4
Statistical analysis
  • Pioglitazone 15 mg and Metformin 850 mg BID vs Glimepiride 2 mg and Metformin 850 mg BID · ANCOVA · p = 0.2203 · Mean difference (final values): -367.2639 · 95% CI -964.3923 to 229.8646
SecondaryChange From Baseline in Platelet Function.

The change between the value of Platelet Function by PFA 100 collected at week 24 or final visit and Platelet Function by PFA 100 collected at baseline.

Time frame:
Baseline and Week 24.
Reported as:
Least squares mean · sec
Change From Baseline in Platelet Function.
secPioglitazone 15 mg and Metformin 850 mg BIDGlimepiride 2 mg and Metformin 850 mg BID
Change From Baseline in Platelet Function.-30.3 ± 44.3-1.0 ± 102.5
Statistical analysis
  • Pioglitazone 15 mg and Metformin 850 mg BID vs Glimepiride 2 mg and Metformin 850 mg BID · ANCOVA · p = 0.5850 · Mean difference (final values): 28.0794 · 95% CI -95.6468 to 151.8057
SecondaryChange From Baseline in E-Selectin.

The change between the value of E-Selectin collected at week 24 or final visit and E-Selectin collected at baseline.

Time frame:
Baseline and Week 24.
Reported as:
Least squares mean · ng/mL
Change From Baseline in E-Selectin.
ng/mLPioglitazone 15 mg and Metformin 850 mg BIDGlimepiride 2 mg and Metformin 850 mg BID
Change From Baseline in E-Selectin.-3.7 ± 4.8-0.5 ± 3.4
Statistical analysis
  • Pioglitazone 15 mg and Metformin 850 mg BID vs Glimepiride 2 mg and Metformin 850 mg BID · ANCOVA · p = 0.0138 · Mean difference (final values): -2.4205 · 95% CI -4.3207 to -0.5202
SecondaryChange From Baseline in Von-Willebrand Factor.

The change between the value of Von-Willebrand Factor collected at week 24 or final visit and Von-Willebrand Factor collected at baseline.

Time frame:
Baseline and Week 24.
Reported as:
Least squares mean · percent
Change From Baseline in Von-Willebrand Factor.
percentPioglitazone 15 mg and Metformin 850 mg BIDGlimepiride 2 mg and Metformin 850 mg BID
Change From Baseline in Von-Willebrand Factor.-19.5 ± 32.01.4 ± 33.2
Statistical analysis
  • Pioglitazone 15 mg and Metformin 850 mg BID vs Glimepiride 2 mg and Metformin 850 mg BID · ANCOVA · p = 0.0817 · Mean difference (final values): 0.0009 · 95% CI -30.1139 to 1.8578
SecondaryChange From Baseline in Erythrocyte Deformability (0.30%).

The change between the 0.30 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.

Time frame:
Baseline and Week 24.
Reported as:
Mean · percent
Change From Baseline in Erythrocyte Deformability (0.30%).
percentPioglitazone 15 mg and Metformin 850 mg BIDGlimepiride 2 mg and Metformin 850 mg BID
Change From Baseline in Erythrocyte Deformability (0.30%).1.3 ± 2.1-0.4 ± 1.7
Statistical analysis
  • Pioglitazone 15 mg and Metformin 850 mg BID vs Glimepiride 2 mg and Metformin 850 mg BID · ANCOVA · p = 0.1761 · Mean difference (final values): 0.9935 · 95% CI -0.4843 to 2.4712
SecondaryChange From Baseline in Erythrocyte Deformability (0.60%)

The change between the 0.60 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.

Time frame:
Baseline and Week 24.
Reported as:
Mean · percent
Change From Baseline in Erythrocyte Deformability (0.60%)
percentPioglitazone 15 mg and Metformin 850 mg BIDGlimepiride 2 mg and Metformin 850 mg BID
Change From Baseline in Erythrocyte Deformability (0.60%)2.4 ± 1.3-0.5 ± 1.1
Statistical analysis
  • Pioglitazone 15 mg and Metformin 850 mg BID vs Glimepiride 2 mg and Metformin 850 mg BID · ANCOVA · p = 0.0002 · Mean difference (final values): 2.5263 · 95% CI 1.3832 to 3.6695
SecondaryChange From Baseline in Erythrocyte Deformability (1.20).

The change between the 1.20 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.

Time frame:
Baseline and Week 24.
Reported as:
Mean · percent
Change From Baseline in Erythrocyte Deformability (1.20).
percentPioglitazone 15 mg and Metformin 850 mg BIDGlimepiride 2 mg and Metformin 850 mg BID
Change From Baseline in Erythrocyte Deformability (1.20).3.2 ± 2.2-1.1 ± 2.5
Statistical analysis
  • Pioglitazone 15 mg and Metformin 850 mg BID vs Glimepiride 2 mg and Metformin 850 mg BID · ANCOVA · p = 0.0055 · Mean difference (final values): 3.2345 · 95% CI 1.0675 to 5.4016
SecondaryChange From Baseline in Erythrocyte Deformability (3.00).

The change between the 3.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.

Time frame:
Baseline and Week 24.
Reported as:
Mean · percent
Change From Baseline in Erythrocyte Deformability (3.00).
percentPioglitazone 15 mg and Metformin 850 mg BIDGlimepiride 2 mg and Metformin 850 mg BID
Change From Baseline in Erythrocyte Deformability (3.00).3.3 ± 2.8-.15 ± 3.1
Statistical analysis
  • Pioglitazone 15 mg and Metformin 850 mg BID vs Glimepiride 2 mg and Metformin 850 mg BID · ANCOVA · p = 0.0264 · Mean difference (final values): 2.9712 · 95% CI 0.3863 to 5.5562
SecondaryChange From Baseline in Erythrocyte Deformability (6.00).

The change between the 6.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.

Time frame:
Baseline and Week 24.
Reported as:
Mean · percent
Change From Baseline in Erythrocyte Deformability (6.00).
percentPioglitazone 15 mg and Metformin 850 mg BIDGlimepiride 2 mg and Metformin 850 mg BID
Change From Baseline in Erythrocyte Deformability (6.00).3.1 ± 2.9-1.4 ± 2.9
Statistical analysis
  • Pioglitazone 15 mg and Metformin 850 mg BID vs Glimepiride 2 mg and Metformin 850 mg BID · ANCOVA · p = 0.0509 · Mean difference (final values): 2.5394 · 95% CI -0.0114 to 5.0901
SecondaryChange From Baseline in Erythrocyte Deformability (12.00).

The change between the 12.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.

Time frame:
Baseline and Week 24.
Reported as:
Mean · percent
Change From Baseline in Erythrocyte Deformability (12.00).
percentPioglitazone 15 mg and Metformin 850 mg BIDGlimepiride 2 mg and Metformin 850 mg BID
Change From Baseline in Erythrocyte Deformability (12.00).2.7 ± 2.8-1.3 ± 2.9
Statistical analysis
  • Pioglitazone 15 mg and Metformin 850 mg BID vs Glimepiride 2 mg and Metformin 850 mg BID · ANCOVA · p = 0.1013 · Mean difference (final values): 2.1718 · 95% CI -0.4660 to 4.8097
SecondaryChange From Baseline in Erythrocyte Deformability (30.00).

The change between the 30.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.

Time frame:
Baseline and Week 24.
Reported as:
Mean · percent
Change From Baseline in Erythrocyte Deformability (30.00).
percentPioglitazone 15 mg and Metformin 850 mg BIDGlimepiride 2 mg and Metformin 850 mg BID
Change From Baseline in Erythrocyte Deformability (30.00).2.5 ± 2.6-1.3 ± 3.5
Statistical analysis
  • Pioglitazone 15 mg and Metformin 850 mg BID vs Glimepiride 2 mg and Metformin 850 mg BID · ANCOVA · p = 0.1363 · Mean difference (final values): 2.1346 · 95% CI -0.7338 to 5.0031
SecondaryChange From Baseline in Erythrocyte Deformability (60.00).

The change between the 60.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.

Time frame:
Baseline and Week 24.
Reported as:
Mean · percent
Change From Baseline in Erythrocyte Deformability (60.00).
percentPioglitazone 15 mg and Metformin 850 mg BIDGlimepiride 2 mg and Metformin 850 mg BID
Change From Baseline in Erythrocyte Deformability (60.00).2.7 ± 2.6-1.3 ± 3.9
Statistical analysis
  • Pioglitazone 15 mg and Metformin 850 mg BID vs Glimepiride 2 mg and Metformin 850 mg BID · ANCOVA · p = 0.1165 · Mean difference (final values): 2.4181 · 95% CI -0.6561 to 5.4922

Adverse events

Collected over 1 year and 11 months. Treatment-emergent adverse events are defined as those occurring after signature of consent form and no more than 14 days after the end of the study.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pioglitazone 15 mg and Metformin 850 mg BID—17/153 (11.1%)61/153 (39.9%)
Glimepiride 2 mg and Metformin 850 mg BID—8/149 (5.4%)61/149 (40.9%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventPioglitazone 15 mg and Metformin 850 mg BIDGlimepiride 2 mg and Metformin 850 mg BID
Cardiac failureCardiac disorders2/1530/149
Abdominal adhesionsGastrointestinal disorders0/1531/149
Carotid artery stenosisNervous system disorders0/1531/149
Coronary artery diseaseCardiac disorders0/1531/149
Hypertensive crisisVascular disorders0/1531/149
Peripheral arterial occlusive diseaseVascular disorders0/1531/149
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1531/149
SubileusGastrointestinal disorders0/1531/149
Urinary retentionRenal and urinary disorders0/1531/149
Benign breast neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1530/149
Most frequent other events
Most frequent other events
EventPioglitazone 15 mg and Metformin 850 mg BIDGlimepiride 2 mg and Metformin 850 mg BID
NasopharyngitisInfections and infestations24/15333/149
DiarrhoeaGastrointestinal disorders14/15314/149
ArthralgiaMusculoskeletal and connective tissue disorders8/1533/149
Oedema peripheralGeneral disorders8/1534/149
HeadacheNervous system disorders7/1537/149

Baseline characteristics

Age Continuous
Age Continuous(years)Pioglitazone 15 mg and Metformin 850 mg BIDGlimepiride 2 mg and Metformin 850 mg BIDTotal
Mean58.7 ± 10.058.5 ± 9.658.6 ± 9.8
Sex: Female, Male
Sex: Female, Male(Participants)Pioglitazone 15 mg and Metformin 850 mg BIDGlimepiride 2 mg and Metformin 850 mg BIDTotal
Female5455109
Male9994193
Region of Enrollment
Region of Enrollment(participants)Pioglitazone 15 mg and Metformin 850 mg BIDGlimepiride 2 mg and Metformin 850 mg BIDTotal
Germany153149302
09

Study locations

64 sites
  • Bretten, Baden-Württemberg, Germany
  • Deggingen, Baden-Württemberg, Germany
  • Dettenheim, Baden-Württemberg, Germany
  • Künzelsau, Baden-Württemberg, Germany
  • Rottweil, Baden-Württemberg, Germany
  • Spaichingen, Baden-Württemberg, Germany
  • Stockach, Baden-Württemberg, Germany
  • Wangen, Baden-Württemberg, Germany
  • Augsburg, Bayern, Germany
  • Feldafing, Bayern, Germany
  • Furth im Wald, Bayern, Germany
  • Immenstadt, Bayern, Germany
  • Lichtenfels, Bayern, Germany
  • München, Bayern, Germany
  • Schweinfurt, Bayern, Germany
  • Waldkraiburg, Bayern, Germany
  • Wallerfing, Bayern, Germany
  • Weilersbach, Bayern, Germany
  • Würzburg, Bayern, Germany
  • Ketzin, Brandenburg, Germany
  • Rüdersdorf, Brandenburg, Germany
  • Bermerhaven, Bremen, Germany
  • Bensheim, Hessen, Germany
  • Ehrenberg, Hessen, Germany
  • Gersfeld, Hessen, Germany
  • Kassel, Hessen, Germany
  • Kelkheim, Hessen, Germany
  • Offenbach, Hessen, Germany
  • Schwerin, Mecklenburg-Vorpommern, Germany
  • Celle, Niedersachsen, Germany
  • Einbeck, Niedersachsen, Germany
  • Hannover, Niedersachsen, Germany
  • Hildesheim, Niedersachsen, Germany
  • Bad Berleburg, Nordrhein-Westfalen, Germany
  • Bad Laasphe, Nordrhein-Westfalen, Germany
  • Bad Oeynhausen, Nordrhein-Westfalen, Germany
  • Bocholt, Nordrhein-Westfalen, Germany
  • Dinslaken, Nordrhein-Westfalen, Germany
  • Dorsten, Nordrhein-Westfalen, Germany
  • Duisburg, Nordrhein-Westfalen, Germany
  • Essen, Nordrhein-Westfalen, Germany
  • Frechen, Nordrhein-Westfalen, Germany
  • Isselburg, Nordrhein-Westfalen, Germany
  • Kamen, Nordrhein-Westfalen, Germany
  • Köln, Nordrhein-Westfalen, Germany
  • Marl, Nordrhein-Westfalen, Germany
  • Menden, Nordrhein-Westfalen, Germany
  • Münster, Nordrhein-Westfalen, Germany
  • Siegen, Nordrhein-Westfalen, Germany
  • Diez, Rheinland-Pfalz, Germany
  • Mainz, Rheinland-Pfalz, Germany
  • Neuwied, Rheinland-Pfalz, Germany
  • Rodenbach, Rheinland-Pfalz, Germany
  • Simmern, Rheinland-Pfalz, Germany
  • Magdeburg, Sachsen-Anhalt, Germany
  • Borna, Sachsen, Germany
  • Dresden, Sachsen, Germany
  • Meißen, Sachsen, Germany
  • Mittweida, Sachsen, Germany
  • Reinfeld, Schleswig-Holstein, Germany
  • Altenburg, Thüringen, Germany
  • Blankenhain, Thüringen, Germany
  • Berlin, Germany
  • Hamburg, Germany
10

References and documents

Publications

  • Pfutzner A, Schondorf T, Tschope D, Lobmann R, Merke J, Muller J, Lehmann U, Fuchs W, Forst T. PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia. Diabetes Technol Ther. 2011 Jun;13(6):637-43. doi: 10.1089/dia.2010.0233. Epub 2011 Apr 2. PubMed 21457065 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2007, a primary completion of May 2009 and a completion of May 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2010, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2008
First posted
Oct 10, 2008
Start
Apr 2007
Primary completionActual
May 2009
CompletionActual
May 2009
Results first posted
Oct 6, 2010
Last update
Oct 6, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00770653
Lead sponsor
Takeda
First posted
Oct 10, 2008
Start date
Apr 2007
Primary completion
May 2009
Completion
May 2009
Results posted
Oct 6, 2010
Last update
Oct 6, 2010

Study contacts

Medical Adviser Clinical Research
study director · Takeda Pharma Gmbh, Aachen (Germany)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pioglitazone · Metformin

Start the discussion